GlassScriptPhysician profile
Cem S Omay
NPI 1053487413
$4,760.74
in general payments reported to CMS, 2019-2025
25 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,075 · 2020: $30.83 · 2021: $718 · 2022: $1,089 · 2023: $263 · 2024: $323 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.45 |
| Education | $130.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $3,012.00 | 2019-2022 | |
| Baxter Healthcare | $490.01 | 2021-2025 | Tisseel |
| Abbvie INC. | $218.15 | 2019-2021 | |
| Organon LLC | $181.36 | 2022-2025 | Jada System, Nexplanon |
| Millicent US INC | $143.90 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $87.22 | 2021-2023 | |
| Intuitive Surgical, INC. | $82.50 | 2021 | |
| Bausch Health US, LLC | $59.08 | 2021-2023 | Aplenzin, Wellbutrin |
| Evofem Biosciences, INC. | $56.24 | 2021-2022 | |
| Therapeuticsmd, INC. | $45.98 | 2019-2021 | |
| Ascend Therapeutics US, LLC | $45.48 | 2022-2023 | |
| Agile Therapeutics, INC. | $44.94 | 2021 | |
| Mimedx Group, INC. | $43.90 | 2025 | |
| Pfizer INC. | $29.30 | 2022 | |
| Allergan, INC. | $29.10 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $29.08 | 2019 | |
| Exeltis, USA INC. | $27.64 | 2022-2023 | Slynd |
| Vertical Pharmaceuticals, LLC | $24.32 | 2019 | |
| Avion Pharmaceuticals | $24.20 | 2019-2021 | |
| Astellas Pharma US INC | $20.55 | 2023 | Veozah |
| Sumitomo Pharma America, INC. | $19.43 | 2023 | Myfembree |
| Davol INC. | $16.96 | 2021 | |
| Ethicon US, LLC | $15.90 | 2020 | |
| Myovant Sciences INC. | $13.50 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cem Omay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.